Elevance Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Elevance Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.13B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $177.01B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $171.34B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $156.60B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $138.64B | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $31.82B | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $31.16B | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $29.26B | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $29.62B | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $27.41B | Feb 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.66B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.98B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $5.99B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $5.89B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $6.16B | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $551.00M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $222.00M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $2.28B | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $1.52B | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $934.00M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $7.86B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $8.50B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $8.28B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $7.56B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.36B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $6.00B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $5.43B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $4.18B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $4.80B | Feb 20, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.98B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $20.03B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $20.09B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $17.70B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $15.92B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $17.45B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $13.36B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $14.02B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $12.65B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $12.56B | Feb 20, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.29B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $5.81B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $8.06B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $8.40B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $8.36B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $10.69B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $6.06B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $3.83B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $4.19B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $3.27B | Feb 20, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.26B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.30B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $1.15B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.02B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.08B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.21B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $791.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $584.00M | Feb 20, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.49B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $116.89B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $108.93B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $102.76B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $97.46B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $86.62B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $77.45B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $71.57B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $70.54B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $65.08B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.47B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $75.46B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $69.52B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $66.43B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $61.33B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $53.42B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $45.73B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $43.03B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $44.04B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $39.98B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.88B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $41.32B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $39.31B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $36.24B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $36.06B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $33.20B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $31.73B | Feb 18, 2021 |
| FY2020 | Dec 31, 2018 | $28.54B | Feb 18, 2021 |
| FY2020 | Dec 31, 2017 | $26.50B | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | $25.10B | Feb 19, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.34B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $28.28B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $25.32B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $24.38B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $24.23B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $21.69B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $20.50B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $20.50B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $19.23B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $17.56B | Feb 20, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.39B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $33.55B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $31.75B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $29.65B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $27.09B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $23.80B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $22.57B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $19.99B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $18.05B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $16.56B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.49B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $8.29B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $6.53B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.39B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.88B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $5.74B | Feb 16, 2022 |
| FY2021 | Dec 31, 2019 | $4.94B | Feb 16, 2022 |
| FY2021 | Dec 31, 2018 | $3.93B | Feb 16, 2022 |
| FY2020 | Dec 31, 2017 | $3.61B | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | $4.08B | Feb 19, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.90B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $30.87B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $24.90B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $23.85B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $22.76B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $20.04B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $19.39B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $18.07B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $18.66B | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | $15.29B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 25 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 25 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 24 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 25 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 9 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 6 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 25 | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | 25 | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | 24 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 24 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 8 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 5 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 220.72M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 227.48M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 233.07M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 237.96M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 241.77M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 245.40M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | 252.92M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 257.40M | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | 256.08M | Feb 20, 2019 |
| FY2017 | Dec 31, 2016 | 263.75M | Feb 21, 2018 |